NLS Pharmaceutics Ltd Ordinary Shares NLSP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NLSP is a good fit for your portfolio.
News
-
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
-
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
-
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
-
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
-
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
-
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
-
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
-
NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies
Trading Information
- Previous Close Price
- $0.13
- Day Range
- $0.12–0.15
- 52-Week Range
- $0.11–1.53
- Bid/Ask
- $0.13 / $0.14
- Market Cap
- $5.92 Mil
- Volume/Avg
- 1,000 / 625,443
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 250
- Website
- https://www.nlspharma.com
Valuation
|
Metric
|
NLSP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NLSP
|
|---|---|
Quick Ratio | 0.44 |
Current Ratio | 0.58 |
Interest Coverage | −167.46 |
Quick Ratio
NLSP
Profitability
|
Metric
|
NLSP
|
|---|---|
Return on Assets (Normalized) | −318.90% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NLSP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bcwzprjjcn | Xvlf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cpjxpxpf | Lrmth | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lbrvvyhw | Lfcsh | $97.8 Bil | |
MRNA
| Moderna Inc | Rbylmmghk | Xrlp | $41.3 Bil | |
ARGX
| argenx SE ADR | Ktmwyglm | Jvyp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dftqmbtfg | Qxzcs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gbwdxdkh | Qymqfb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ryzgnnf | Tsvhzb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fflgrdhdp | Nxvnb | $12.5 Bil | |
INCY
| Incyte Corp | Xdbtjml | Ltyylp | $11.6 Bil |